Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

Abstract Objective Intra-tumoral heterogeneity of 18F‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Guang Ma, Shuhui You, Yizhao Xie, Bingxin Gu, Cheng Liu, Xichun Hu, Shaoli Song, Biyun wang, Zhongyi Yang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-09-01
coleção:	Cancer Imaging
Assuntos:	Heterogeneity of 18F-FDG uptake Prognosis Metastatic HER2 positive breast cancer Dual target therapy
Acesso em linha:	https://doi.org/10.1186/s40644-023-00608-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!